Palisade Bio, Inc. (PALI) AI Stock Analysis

Palisade Bio, Inc., established in 2005 and headquartered in Carlsbad, California, is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing oral therapies for severe diseases linked to the breakdown of the mucosal barrier safeguarding the gastrointestinal tract. The company's primary therapeutic candidate is LB1148, an oral liquid formulation of tranexamic acid. LB1148 is a digestive enzyme inhibitor designed to reduce abdominal adhesions in gastrointestinal tissues and accelerate post-surgical bowel function recovery. Palisade Bio advances LB1148 and other pipeline candidates through clinical trials and regulatory pathways to address critical medical needs in gastrointestinal healthcare.

Palisade Bio generated revenue of $260,000 in FY2018, which dropped 94.1% to $15,394 in FY2019 and fell 12.2% to $13,520 in FY2020. Revenue grew 1749.1% to $250,000 in FY2022 and held flat at $250,000 in FY2023 with a 0.0% growth rate. From FY2017 to FY2023, the five-year revenue CAGR was -0.8%. Operating margins were deeply negative across this period, registering -3176.5% in FY2018, -6288.4% in FY2022, and -5228.0% in FY2023. Annual net income was -$4.9M in FY2018, -$14.3M in FY2022, and -$12.3M in FY2023. In the trailing twelve months ended June 30, 2026, revenue stood at $500,000, operating margin was -2339.6%, and EPS was $0.60.

As of June 30, 2026, Palisade Bio held $125.2M in cash and short-term investments, total assets of $127.3M, and shareholders' equity of $121.7M. Liquidity remains high with a current ratio of 24.26. Operating cash flow in FY2023 was -$11.1M, matching free cash flow of -$11.1M, following R&D expenses of $6.9M. In FY2025, cash from share issuance was $19,000, and the company's share count expanded by 77987.2% over a five-year span.

Palisade Bio trades at a market capitalization of $245.7M and an enterprise value of $148.5M. Its trailing price-to-earnings multiple of 2.4x is below the median of its US-listed Healthcare peers of 24.6x, while its EV/EBITDA of 0.6x is lower than the peer median of 12.0x. Conversely, its price-to-sales ratio of 491.4x is far above the peer median of 4.1x. Over the past year, the stock fell 18.5%, trailing the S&P 500 return of 16.8%. Over five years, shares dropped 99.9%, compared to an 83.0% gain for the S&P 500.

Analyst coverage on Palisade Bio includes 7 Strong Buy ratings, 3 Buy ratings, and 0 Hold, Sell, or Strong Sell ratings. The mean price target of $9.80 represents a 595.0% premium over the October 16, 2026 close of $1.41. For FY2026, analysts estimate an EPS of -$0.22 on revenue of $437,500. For the next fiscal year, 8 analysts project EPS of -$0.28 and revenue of $0, representing a revenue decline of 100.0%. Over the last four quarters, the company delivered 0 EPS beats. The next earnings date is November 9, 2026.

This page is an AI-written research summary of Palisade Bio, Inc. (PALI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PALI income statement, PALI balance sheet, PALI key metrics, PALI analyst forecast, PALI chart. See the PALI stock overview for the latest quote and news.